WASHINGTON, May 6 (Reuters) - A U.S. Food and Drug Administration advisory panel on Thursday :
* said Questcor Pharmaceuticals Inc has not provided substantial
evidence that Acthar's side effects are manageable, reversible
* voted 10-12 with one abstention against side effect data for
Questcor's Acthar in infant spasms
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* said Questcor Pharmaceuticals Inc has not provided substantial
evidence that Acthar's side effects are manageable, reversible
* voted 10-12 with one abstention against side effect data for
Questcor's Acthar in infant spasms
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.